CytomX CTMX
Valuation
Multiples measured against the stock's own five-year history
Below its usual level · 25th percentile, 5-year average -8.0x
Around its usual level · 46th percentile, 5-year average -2.3x
#2561 of 5329 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 97th percentile, 5-year average 5.2x
#4812 of 5156 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 1.56 | – | -2.31 | 46% (cheaper than usual) | #2561 of 5329 (1 = cheapest) |
| PE | -4.00 | -4.30 | -8.02 | 25% (cheaper than usual) | – |
| PS | 31.70 | 15.52 | 5.21 | 97% (pricier than usual) | #4812 of 5156 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on CTMX.
Sign in to join the discussion.